145 related articles for article (PubMed ID: 21223693)
1. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract][Full Text] [Related]
2. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
3. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
4. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
6. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
7. [Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Chen T; Chu ZH; Liu JP; Wang J; Zhao HY; Ou QJ
Ai Zheng; 2005 Aug; 24(8):1018-22. PubMed ID: 16086886
[TBL] [Abstract][Full Text] [Related]
8. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
9. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sharma S; Neale MH; Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Higgins BR; Lamont A; Osborne R; Hindley AC; Kurbacher CM; Cree IA
BMC Cancer; 2003 Jul; 3():19. PubMed ID: 12841853
[TBL] [Abstract][Full Text] [Related]
10. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
[TBL] [Abstract][Full Text] [Related]
11. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
[TBL] [Abstract][Full Text] [Related]
12. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
14. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
[TBL] [Abstract][Full Text] [Related]
15. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Xu X; Dai H; Zhao Y; Wang Y; Xu X; Qian Z; Chen X
Eur J Gynaecol Oncol; 2013; 34(6):559-64. PubMed ID: 24601052
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Han SS; Choi SH; Lee YK; Kim JW; Park NH; Song YS; Lee HP; Kang SB
Cancer Invest; 2008 May; 26(4):426-30. PubMed ID: 18443964
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Glaysher S; Gabriel FG; Johnson P; Polak M; Knight LA; Parker K; Poole M; Narayanan A; Cree IA;
Br J Cancer; 2010 Aug; 103(5):656-62. PubMed ID: 20700122
[TBL] [Abstract][Full Text] [Related]
19. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
[TBL] [Abstract][Full Text] [Related]
20. The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
Neale MH; Lamont A; Hindley A; Kurbacher CM; Cree IA
Anticancer Drugs; 2000 Nov; 11(10):865-71. PubMed ID: 11142695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]